Technical Analysis for NTRA - Natera, Inc.

Grade Last Price % Change Price Change
grade B 19.21 -2.39% -0.47
NTRA closed down 2.39 percent on Monday, March 25, 2019, on 51 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical NTRA trend table...

Date Alert Name Type % Chg
Mar 25 200 DMA Support Bullish 0.00%
Mar 25 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 25 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 25 Wide Bands Range Expansion 0.00%
Mar 25 Overbought Stochastic Strength 0.00%
Mar 22 Multiple of Ten Bearish Other -2.39%
Mar 22 Wide Bands Range Expansion -2.39%
Mar 22 Overbought Stochastic Strength -2.39%
Mar 21 Calm After Storm Range Contraction -6.25%
Mar 21 Narrow Range Bar Range Contraction -6.25%

Older signals for NTRA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Medicine Clinical Medicine Medical Genetics Medical Tests Applied Genetics DNA Genetic Testing DNA Paternity Testing In Vitro Fertilization
Is NTRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.62
52 Week Low 8.6
Average Volume 588,924
200-Day Moving Average 19.0551
50-Day Moving Average 15.8318
20-Day Moving Average 17.566
10-Day Moving Average 19.381
Average True Range 1.0476
ADX 33.26
+DI 30.819
-DI 16.4299
Chandelier Exit (Long, 3 ATRs ) 17.6372
Chandelier Exit (Short, 3 ATRs ) 17.8528
Upper Bollinger Band 21.5488
Lower Bollinger Band 13.5832
Percent B (%b) 0.71
BandWidth 45.346692
MACD Line 1.2288
MACD Signal Line 1.0497
MACD Histogram 0.1791
Fundamentals Value
Market Cap 1.02 Billion
Num Shares 53.2 Million
EPS -2.43
Price-to-Earnings (P/E) Ratio -7.91
Price-to-Sales 2.91
Price-to-Book 11.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.41
Resistance 3 (R3) 20.45 20.08 20.21
Resistance 2 (R2) 20.08 19.78 20.07 20.14
Resistance 1 (R1) 19.65 19.59 19.47 19.61 20.08
Pivot Point 19.28 19.28 19.19 19.27 19.28
Support 1 (S1) 18.85 18.98 18.67 18.81 18.34
Support 2 (S2) 18.48 18.79 18.47 18.28
Support 3 (S3) 18.05 18.48 18.21
Support 4 (S4) 18.01